Patents by Inventor Leah Elizabeth Appel

Leah Elizabeth Appel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Taste-masked drugs in rupturing multiparticulates
    Patent number: 8236349
    Abstract: A pharmaceutical composition comprises multiparticulates comprising a drug, a matrix material, and swelling agent. In one aspect, the multiparticulates comprise a core comprising a drug, and a coating surrounding the core. The coating is selected from the group consisting of (i) a water-permeable, substantially drug-impermeable coating, and (ii) an anti-enteric coating.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: August 7, 2012
    Assignee: Bend Research Inc.
    Inventors: Leah Elizabeth Appel, Dwayne Thomas Friesen, Edward Dennis LaChapelle, Sanjay Konagurthu, Richard Frank Falk, Joseph P. Reo
  • MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE
    Publication number: 20110027372
    Abstract: Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.
    Type: Application
    Filed: October 11, 2010
    Publication date: February 3, 2011
    Inventors: Leah Elizabeth Appel, Dwayne Thomas Friesen, David Keith Lyon, Scott Baldwin McCray, Joshua Richard Shockey
  • DOSAGE FORMS COMPRISING CELECOXIB PROVIDING BOTH RAPID AND SUSTAINED PAIN RELIEF
    Publication number: 20100233272
    Abstract: A pharmaceutical dosage form comprising celecoxib and a pharmaceutically acceptable carrier, the dosage form when initially administered to at least 12 human patients in the fasted state in a crossover study providing: (a) a mean blood plasma concentration of celecoxib within 0.5 hour after administration (C0.5) of at least about 0.9 ng/ml per mg of celecoxib dosed; (b) a mean blood plasma concentration of celecoxib 12 hours after administration (Ci2) of at least about 0.6 ng/ml per mg of celecoxib dosed; (c) a mean area under the blood plasma concentration versus time curve for the 12 hour period following administration (AUC12) of at least 19 ng-hr/mL per mg of celecoxib dosed; and (d) a mean maximum blood plasma concentration (Cmax) of celecoxib of less than about 4.9 ng/ml per mg of celecoxib dosed.
    Type: Application
    Filed: November 6, 2008
    Publication date: September 16, 2010
    Inventors: Leah Elizabeth Appel, Dwayne Thomas Friesen, Scott M. Herbig, Rodney James Ketner, Sheri L. Shamblin
  • SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE
    Publication number: 20100003331
    Abstract: A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 3, 2009
    Publication date: January 7, 2010
    Applicant: Pfizer Inc.
    Inventors: Imran Ahmed, Leah Elizabeth Appel, Walter Christian Babcock, Dwayne Thomas Friesen, Scott Herbig, David Keith Lyon, Sheri L. Shamblin, Ravi Mysore Shanker, Daniel Tod Smithey, Steven C. Sutton, Avinash Govind Thombre, Kenneth C. Waterman, Jaymin C. Shah, Parag Suresh Shah, Peter Wisniecki, Dawn Renee Wagner
  • Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
    Publication number: 20090142401
    Abstract: Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.
    Type: Application
    Filed: May 26, 2006
    Publication date: June 4, 2009
    Inventors: Leah Elizabeth Appel, Dwayne Thomas Friesen, David Keith Lyon, Scott Baldwin McCray, Joshua Richard Shockey
  • Azithromycin dosage forms with reduced side effects
    Patent number: 6984403
    Abstract: The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: January 10, 2006
    Assignee: Pfizer Inc.
    Inventors: Timothy A. Hagen, Julian B. Lo, Avinash G. Thombre, Scott M. Herbig, Leah Elizabeth Appel, Marshall David Crew, Dwayne Thomas Friesen, David Keith Lyon, Scott Baldwin McCray, James Blair West